The advent of anti-VEGF therapy for cancer, specifically bevacizumab (IVB; Avastin; Genentech; South San Francisco, CA, USA), led to the use of the same drug in exudative AMD (eAMD) and was found to be highly effective. This evidence concerns the gene VEGFA and cancer.